← All trials
NCT04819685
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2021
- Primary completion
- Mar 1, 2023
- Completion date
- Mar 1, 2025
- First posted
- Mar 29, 2021
- Last posted
- Mar 29, 2021
- Enrollment
- 520
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Peking UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Central South UniversityCollaborator
- Shandong UniversityCollaborator
- Fudan UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Sun Yat-Sen UniversityCollaborator
- Henan Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Jilin Provincial Tumor HospitalCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Jiangsu Cancer Institute & HospitalCollaborator
- People's Liberation Army of ChinaCollaborator
- Guizhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.